Search bioRxiv⌕ Search

Biology subjects

Shahneh, F.

Publications and source records attributed to Shahneh, F..

2 recordsLinked to original sources

Macrophage-mediated bystander T cell activation in varicose veins

Background: Up to one-third of all adults are affected by chronic venous insufficiency, with varicose veins being a common manifestation of the condition. It is believed that inflammation plays a central role in the progression of the disease; however, the immune cell populations and mechanisms involved remain unclear. Methods: Varicose veins were subjected to a stepwise mechanical and enzymatic dissociation, and the mononuclear cells resulting from these steps were characterized by flow cytometry. CD206-negative connective tissue macrophages and CD206-positive venous wall macrophages were sorted from five donors and subjected to transcriptomic profiling. Cytokine production by T cells in varicose veins was characterized following inhibition of intracellular protein transport. The ability of cytokines identified in macrophage transcriptomes to induce cytokine production in CD8+ and CD4+ effector and memory T cells was investigated using combinations of recombinant cytokines. Results: Varicose veins harbor CD206neg IL-1+ S100A8/9+ macrophages in the connective tissue and pro-resolving and tissue regenerating CD206+ TIMD4+ LYVE1+ macrophages in the vein wall. T cells predominantly localize within the connective tissue, express an effector-memory T cell phenotype and produce IFN-{gamma} in situ. Cytokines identified in the macrophage transcriptome collectively induced IFN-{gamma}, as well as TNF-, IL-22, and GM-CSF in effector memory T cells; in addition to IL-15 and IL-18, TNF- and IL-10 proved to be key drivers. Conclusions: The identified macrophage-T cell cytokine axis contributes to chronic venous insufficiency pathogenesis and represents a potential therapeutic target.

immunology↗

KDM6B inhibition modulates monocyte activation and alleviates IMQ-psoriasis skin inflammation

Inflammatory monocytes are increasingly recognized as key amplifiers of psoriasis, yet the epigenetic drivers of their pathogenic signature remain unclear. Here, we demonstrate that the histone demethylase KDM6B is markedly upregulated and catalytically active in classical monocytes during the imiquimod (IMQ)-induced psoriasis model. This is associated with reduced levels of the repressive histone mark H3K27me3, an epigenetic modification linked to chromatin compaction and transcriptional silencing, at the Il1b, Tnf, Pgam1, Pgk1, and Aldoa promoters, together with an enhanced inflammatory and glycolytic gene signature. Pharmacological blockade of KDM6B after disease onset using GSK-J4, a cell-permeable prodrug that is intracellularly converted to the active KDM6B inhibitor GSK-J1, restores H3K27me3 at inflammatory and metabolic loci, suppresses Il1b/Tnf transcription, normalizes bioenergetic profiles, and reduces monocyte and neutrophil recruitment to the inflamed skin. Single-cell transcriptomic profiling further reveals that KDM6B inhibition represses cytokine-mediated signaling, glycolysis, and chemotaxis pathways in monocytes, yet enriches antigen presentation modules, consistent with a shift toward a homeostatic, antigen-presenting surveillance program in myeloid cells and a Treg-supportive milieu. Collectively, our data identify KDM6B as an epigenetic-metabolic switch that sustains monocyte-driven inflammation in the IMQ-induced psoriasis model. Importantly, we provide preclinical evidence that targeting KDM6B can reduce maladaptive inflammatory response even in progressed diseases. These findings propose KDM6B inhibitors as a promising adjunct to current biologics for psoriasis and other myeloid-driven autoinflammatory disorders. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=178 HEIGHT=200 SRC="FIGDIR/small/682023v1_ufig1.gif" ALT="Figure 1"> View larger version (58K): org.highwire.dtl.DTLVardef@efef15org.highwire.dtl.DTLVardef@395983org.highwire.dtl.DTLVardef@123e832org.highwire.dtl.DTLVardef@615f84_HPS_FORMAT_FIGEXP M_FIG C_FIG

immunology↗